Similar articles

• Vioxx's history and the need for better procedures and better testing.

  Gilhooley M. Gilhooley M. Seton Hall Law Rev. 2007;37(4):941-68. Seton Hall Law Rev. 2007. PMID: 18363218 No abstract available.
• The Vioxx® legacy: Enduring lessons from the not so distant past.

  McIntyre WF, Evans G. McIntyre WF, et al. Cardiol J. 2014;21(2):203-5. doi: 10.5603/CJ.2014.0029. Cardiol J. 2014. PMID: 24752949 No abstract available.
• Rofecoxib, Merck, and the FDA.

  Kim PS, Reicin AS. Kim PS, et al. N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. doi: 10.1056/NEJM200412303512719. N Engl J Med. 2004. PMID: 15625342 No abstract available.
• [New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].

  Oliw E, Wollheim FA. Oliw E, et al. Lakartidningen. 2000 Jun 14;97(24):2942-4. Lakartidningen. 2000. PMID: 10900877 Review. Swedish. No abstract available.
• Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

  Weir MR, Sperling RS, Reicin A, Gertz BJ. Weir MR, et al. Am Heart J. 2003 Oct;146(4):591-604. doi: 10.1016/S0002-8703(03)00398-3. Am Heart J. 2003. PMID: 14564311 Review.